CG Oncology Soars 36.34% on Bladder Cancer Drug Data

On April 28, 2025, CG Oncology's stock surged by 36.34% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

CG Oncology recently announced impressive durability data from its BOND-003 Cohort C, showcasing the effectiveness of Cretostimogene Grenadenorepvec in treating bladder cancer. The study revealed a median duration of response of 28 months, with 97.3% of patients remaining free from progression to muscle-invasive bladder cancer at the 24-month mark. This data underscores the potential of Cretostimogene Grenadenorepvec as a groundbreaking treatment option, contributing to the stock's positive momentum.

Additionally, the company reported a 75.5% complete response rate at any time, with 34 confirmed complete responses at 24 months and 9 patients pending their 24-month assessment. These findings further solidify the therapeutic benefits of Cretostimogene Grenadenorepvec, reinforcing investor confidence in CG Oncology's innovative approach to cancer treatment.